Promotional materials for triple combination therapy of Prilosec (omeprazole), Biaxin (clarithromycin) and amoxicillin overstates efficacy of the Helicobacter pylori regimen, FDA maintains in a May 21 letter. The statement in a "patient information pak" that "If you stop taking your medicines too soon and don't eliminate all the H. pylori, your ulcer is likely to return" implies that patients' ulcers will not return, which is misleading, FDA notes. The agency points out that in clinical trials, the eradication rate was 5% to 35%. "These recurrence rates indicate that patients in whom the H. pylori organism has been eradicated may still experience a recurrence of their duodenal ulcer," FDA says. The letter also cites the company for selectively presenting more favorable efficacy rates for triple therapy with Prilosec of 77% to 90%, when clinical trials showed a wider range of efficacy from 69% to 90% by intent-to-treat analysis. The pak box also fails to present information on contraindications for the triple therapy
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth